Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

10.58
-0.1900-1.76%
Post-market: 10.620.0400+0.38%18:19 EDT
Volume:3.72M
Turnover:38.27M
Market Cap:900.43M
PE:-2.77
High:10.80
Open:10.75
Low:10.00
Close:10.77
52wk High:23.29
52wk Low:8.80
Shares:85.11M
Float Shares:55.47M
Volume Ratio:1.97
T/O Rate:6.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8139
EPS(LYR):-3.5300
ROE:-67.47%
ROA:-32.44%
PB:2.10
PE(LYR):-3.00

Loading ...

MoonLake Immunotherapeutics Could Win FDA Approval for Sonelokimab by Year-End 2027, Wedbush Says

MT Newswires Live
·
Oct 05

MoonLake Immunotherap Price Target Maintained with a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
Oct 05

MoonLake Immunotherapeutics - Submits Bla to FDA for Sonelokimab to Treat Hidradenitis Suppurativa - SEC Filing

THOMSON REUTERS
·
Oct 01

MoonLake Submits FDA BLA for Sonelokimab in Hidradenitis Suppurativa

Reuters
·
Oct 01

H.C. Wainwright Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Aug 13

MoonLake Immunotherapeutics : H.c. Wainwright Raises Target Price to $50 from $45

THOMSON REUTERS
·
Aug 13

MoonLake Immunotherapeutics (MLTX) Receives a Hold from RBC Capital

TIPRANKS
·
Aug 12

Guggenheim Reaffirms Their Buy Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
Aug 11

MoonLake Immunotherapeutics: Files for Mixed Shelf Offering, Size not Disclosed - SEC Filing

THOMSON REUTERS
·
Aug 11

MoonLake Immunotherapeutics Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 10

MoonLake Immunotherapeutics Q2 Loss Narrows, Phase 3 PsA Trial Meets Clinical Goals

MT Newswires Live
·
Aug 10

MoonLake's Psoriatic Arthritis Drug Meets Key Goals in Late-Stage Trial

Reuters
·
Aug 10

MoonLake Q2 FY26 Net Loss Widens 10.3% to $61.81 Million

Reuters
·
Aug 10

MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16

TIPRANKS
·
Aug 10

MoonLake Q2 EPS $(0.84) Beats $(0.93) Estimate

Benzinga Earnings
·
Aug 10

Switzerland's MoonLake Q2 Net Loss Narrows as Expenses Fall

Reuters
·
Aug 10

MoonLake Immunotherapeutics - Blinded Safety Analysis Shows no New Safety Signals for Sonelokimab

THOMSON REUTERS
·
Aug 10

MoonLake Immunotherapeutics - Acr50 Primary Endpoint Met with 42.1% Response for Sonelokimab 60 Mg

THOMSON REUTERS
·
Aug 10

MoonLake Immunotherapeutics - Phase 3 Izar-1 Trial Meets All Clinical Endpoints at Week 16 for 60 Mg Sonelokimab

THOMSON REUTERS
·
Aug 10

MoonLake Immunotherapeutics Q2 EPS USD -0.84

THOMSON REUTERS
·
Aug 10